Screener
Assembly Biosciences ASMB Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 232,613 | 254,549 |
| Property and equipment, net | 214 | 221 |
| Operating lease right-of-use (ROU) assets | 2,369 | 2,508 |
| Other assets | 312 | 312 |
| Total assets | $235,508 | $257,590 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $1,129 | $1,171 |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's deferred tax assets and other non-current assets?
- Assembly Biosciences (ASMB) reported deferred tax assets and other non-current assets of $312K in Q1 2026.
- How has Assembly Biosciences's deferred tax assets and other non-current assets changed year-over-year?
- Assembly Biosciences's deferred tax assets and other non-current assets decreased by 0.0% year-over-year, from $312K to $312K.
- What is the long-term trend for Assembly Biosciences's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Assembly Biosciences's deferred tax assets and other non-current assets has grown at a -45.3% compound annual growth rate (CAGR), from $6.39M to $312K.
Ask your AI about Assembly Biosciences's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude